Screener
Collegium Pharmaceutical, Inc. COLL Azstarys — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Jornay PM | 46,058 | 32,626 | 84,951 | 61,165 |
| Nucynta IR | 14,356 | 26,501 | 40,434 | 53,918 |
| Nucynta ER | 15,723 | 19,946 | 33,957 | 39,632 |
| Azstarys | 12,910 | — | 12,910 | — |
| Symproic | 3,020 | 3,722 | 7,213 | 6,537 |
| Nucynta ER AG | 2,775 | — | 4,221 | — |
| Nucynta IR AG | 2,361 | — | 3,619 | — |
| Total product revenues, net | $199,878 | $188,000 | $393,398 | $365,757 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s azstarys — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported azstarys — product revenues, net of $12.91M in Q2 2026.
- What does azstarys — product revenues, net mean?
- Represents the total net sales generated from the Azstarys product line after accounting for returns, allowances, and rebates. This metric is a key indicator of the product's market adoption and commercial success within the company's portfolio.
Ask your AI about Collegium Pharmaceutical, Inc.'s azstarys — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude